# 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/2-year-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ian Smith,Marion Procter,Richard D. Gelber,Sébastien Guillaume,A. Feyereislova,Mitch Dowsett,Aron Goldhirsch,Michael Untch,Gabriella Mariani,José Baselga,Manfred Kaufmann,David Cameron,Richard H. Bell,Jonas Bergh,Robert L. Coleman,Andrew Wardley,Nadia Harbeck,R.I. Lopez,Peter Mallmann,Karen A. Gelmon,Nicholas Wilcken,Erik Wist,Pedro Sánchez‐Rovira,Martine Piccart |
| Citations | 1,514 |
| DOI | 10.1016/s0140-6736(07)60028-2 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2045324973 |
| PMID | 17208639 |
| Type | article |
| Year | 2007 |

## Paper authors

- [Robert L. Coleman](https://scholariq.org/researchers/robert-l-coleman/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.